Skip to content
Storytelling Co – Lifestyle
Author:
SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update
November 12, 2026
SELLAS Life Sciences to Present Positive Phase 2 Data Demonstrating Encouraging Response and Survival Outcomes with SLS009 Combination in High-Risk AML at ASH 2026
November 4, 2026
SELLAS Life Sciences Reaches 80th Event in Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia
October 28, 2026
SELLAS Life Sciences Presents Preclinical Data Demonstrating SLS009 Activity in Pancreatic Cancer Models at the 2026 AACR Conference on Pancreatic Cancer
September 25, 2026
SELLAS Life Sciences to Present Preclinical Data on SLS009 in Pancreatic Ductal Adenocarcinoma at the 2026 AACR Conference on Pancreatic Cancer
September 2, 2026
SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 11, 2026